Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
41
BHC Quote, Financials, Valuation and Earnings
Last price:
$6.08
Seasonality move
:
-3.4%
Day range:
$5.97 - $6.20
52-week range:
$4.25 - $8.69
Dividend yield:
0%
P/E ratio:
6.27x
P/S ratio:
0.23x
P/B ratio:
--
Volume:
2.5M
Avg. volume:
2.1M
1-year change:
-4.55%
Market cap:
$2.3B
Revenue:
$9.6B
EPS (TTM):
$0.97
Analysts' Opinion
-
Consensus RatingBausch Health Cos., Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.43, Bausch Health Cos., Inc. has an estimated upside of 22.18% from its current price of $6.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $6.08.
Fair Value
-
According to the consensus of 7 analysts, Bausch Health Cos., Inc. has 22.18% upside to fair value with a price target of $7.43 per share.
BHC vs. S&P 500
-
Over the past 5 trading days, Bausch Health Cos., Inc. has overperformed the S&P 500 by 7.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bausch Health Cos., Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bausch Health Cos., Inc. has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Bausch Health Cos., Inc. reported revenues of $2.7B.
Earnings Growth
-
Bausch Health Cos., Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Bausch Health Cos., Inc. reported earnings per share of $0.48.
Enterprise value:
22.9B
EV / Invested capital:
--
Price / LTM sales:
0.23x
EV / EBIT:
11.13x
EV / Revenue:
2.28x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
22.13x
Price / Operating cash flow:
2.18x
Enterprise value / EBITDA:
6.97x
Gross Profit (TTM):
$6.1B
Return On Assets:
1.2%
Net Income Margin (TTM):
3.2%
Return On Equity:
--
Return On Invested Capital:
1.5%
Operating Margin:
26.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $8.5B | $9.5B | $10B | $2.5B | $2.7B | |
| Gross Profit | $4.9B | $5.6B | $6.1B | $1.5B | $1.7B | |
| Operating Income | $1.5B | $1.8B | $2.1B | $544M | $717M | |
| EBITDA | $2.8B | $3.1B | $3.3B | $866M | $1B | |
| Diluted EPS | -$2.65 | -$0.49 | $0.97 | -$0.23 | $0.48 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.3B | $4B | $5B | $5.4B | $6.2B | |
| Total Assets | $29.3B | $26.3B | $27.1B | $26.5B | $26.8B | |
| Current Liabilities | $5.4B | $3.8B | $4.2B | $4.5B | $4.8B | |
| Total Liabilities | $29.4B | $25.9B | $27.3B | $26.8B | $26.5B | |
| Total Equity | -$135M | $433M | -$235M | -$242M | $356M | |
| Total Debt | $22.4B | $21.2B | $22.4B | $21.5B | $21B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1B | $1.4B | $1.5B | $400.5M | $408.1M | |
| Cash From Investing | -$2.1B | -$404.3M | -$509.5M | -$101.6M | -$83.8M | |
| Cash From Financing | $1.3B | -$1B | -$379.3M | -$185.3M | -$728.6M | |
| Free Cash Flow | $822.3M | $998.3M | $1B | $329.7M | $316.2M | |
BHC
Sector
Market Cap
$2.3B
$24.1M
Price % of 52-Week High
70.01%
49.1%
Dividend Yield
0%
0%
Shareholder Yield
5.17%
-1.67%
1-Year Price Total Return
-4.55%
-21.71%
Beta (5-Year)
0.416
0.502
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.87
200-day SMA
Sell
Level
$6.34
Bollinger Bands (100)
Sell
Level
6.04 - 7.1
Chaikin Money Flow
Sell
Level
-866.3M
20-day SMA
Sell
Level
$6.15
Relative Strength Index (RSI14)
Sell
Level
43.99
ADX Line
Sell
Level
28.45
Williams %R
Neutral
Level
-29.6053
50-day SMA
Sell
Level
$6.74
MACD (12, 26)
Sell
Level
-0.27
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-194.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.097)
Sell
CA Score
(Annual)
Level (-2.5068)
Buy
Beneish M-Score
(Annual)
Level (-2.732)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.3668)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Stock Forecast FAQ
In the current month, BHC has received 0 Buy ratings 7 Hold ratings, and 0 Sell ratings. The BHC average analyst price target in the past 3 months is $7.43.
-
Where Will Bausch Health Cos., Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bausch Health Cos., Inc. share price will rise to $7.43 per share over the next 12 months.
-
What Do Analysts Say About Bausch Health Cos., Inc.?
Analysts are divided on their view about Bausch Health Cos., Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bausch Health Cos., Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Bausch Health Cos., Inc.'s Price Target?
The price target for Bausch Health Cos., Inc. over the next 1-year time period is forecast to be $7.43 according to 7 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is BHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bausch Health Cos., Inc. is a Hold. 7 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BHC?
You can purchase shares of Bausch Health Cos., Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bausch Health Cos., Inc. shares.
-
What Is The Bausch Health Cos., Inc. Share Price Today?
Bausch Health Cos., Inc. was last trading at $6.08 per share. This represents the most recent stock quote for Bausch Health Cos., Inc.. Yesterday, Bausch Health Cos., Inc. closed at $6.08 per share.
-
How To Buy Bausch Health Cos., Inc. Stock Online?
In order to purchase Bausch Health Cos., Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BHC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BHC
Sector
P/E ratio
6.27x
23.23x
PEG ratio
-0.03x
-0.01x
P/B ratio
--
1.75x
Price / LTM sales
0.23x
1.50x
Growth Metrics
BHC
Sector
Revenue growth
6.81%
3.24%
Earnings growth
306.63%
10.12%
Revenue (5-year growth)
2.28%
6.27%
Earnings forecast
$1.26
-$0.19
Profitability
BHC
Sector
Profitability FY 2024
$5.8B
$2.7M
Return on invested capital
1.5%
-33.65%
Return on assets
1.2%
-29.68%
Return on equity
--
-38.98%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
18
Estimated Next Earnings Date
Jan
28
Balance Sheet
BHC
Sector
Total cash
$1.3B
$25M
Short term investments
--
$23.9M
Total assets
$26.5B
$72.5M
Long term debt
$21B
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
73
NKTR alert for Feb 12
Nektar Therapeutics [NKTR] is up 18.79% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is up 26.39% over the past day.
Buy
73
AEHR alert for Feb 12
Aehr Test Systems [AEHR] is up 26.09% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
